Dova Pharmaceuticals Inc (NASDAQ:DOVA) Major Shareholder Life Sciences Maste Perceptive Acquires 50,000 Shares

Share on StockTwits

Dova Pharmaceuticals Inc (NASDAQ:DOVA) major shareholder Life Sciences Maste Perceptive bought 50,000 shares of the company’s stock in a transaction dated Friday, July 5th. The shares were acquired at an average price of $16.46 per share, for a total transaction of $823,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Life Sciences Maste Perceptive also recently made the following trade(s):

  • On Wednesday, July 3rd, Life Sciences Maste Perceptive bought 20,541 shares of Dova Pharmaceuticals stock. The shares were acquired at an average price of $14.51 per share, for a total transaction of $298,049.91.
  • On Friday, June 28th, Life Sciences Maste Perceptive bought 427,209 shares of Dova Pharmaceuticals stock. The shares were acquired at an average price of $13.35 per share, for a total transaction of $5,703,240.15.

DOVA stock opened at $16.75 on Friday. The company has a current ratio of 4.46, a quick ratio of 4.27 and a debt-to-equity ratio of 0.20. Dova Pharmaceuticals Inc has a 12-month low of $5.62 and a 12-month high of $26.49. The firm has a market cap of $474.60 million, a PE ratio of -6.44 and a beta of 2.55. The business has a 50-day moving average price of $11.21.

Dova Pharmaceuticals (NASDAQ:DOVA) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.68) by $0.10. Dova Pharmaceuticals had a negative return on equity of 87.20% and a negative net margin of 521.67%. The company had revenue of $4.00 million for the quarter, compared to analysts’ expectations of $3.46 million. As a group, equities research analysts anticipate that Dova Pharmaceuticals Inc will post -2.1 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DOVA. Broadfin Capital LLC purchased a new position in Dova Pharmaceuticals in the 4th quarter worth approximately $2,667,000. Sanders Morris Harris LLC purchased a new position in Dova Pharmaceuticals in the 1st quarter worth approximately $2,507,000. Sphera Funds Management LTD. lifted its stake in Dova Pharmaceuticals by 54.2% in the 4th quarter. Sphera Funds Management LTD. now owns 185,000 shares of the company’s stock worth $1,402,000 after purchasing an additional 65,000 shares in the last quarter. Spark Investment Management LLC lifted its stake in Dova Pharmaceuticals by 31.8% in the 1st quarter. Spark Investment Management LLC now owns 80,500 shares of the company’s stock worth $715,000 after purchasing an additional 19,400 shares in the last quarter. Finally, Squarepoint Ops LLC purchased a new position in Dova Pharmaceuticals in the 4th quarter worth approximately $137,000. 30.18% of the stock is currently owned by institutional investors and hedge funds.

Several equities research analysts recently issued reports on DOVA shares. Wedbush set a $190.00 price objective on Home Depot and gave the stock a “hold” rating in a report on Wednesday, May 22nd. BidaskClub upgraded Zillow Group from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 2nd. Zacks Investment Research cut ExlService from a “hold” rating to a “sell” rating in a report on Wednesday. HC Wainwright lifted their price objective on Dova Pharmaceuticals from $18.00 to $39.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. Finally, Evercore ISI upgraded Dova Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $15.00 price objective on the stock in a report on Monday, July 1st. Two research analysts have rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $29.11.

About Dova Pharmaceuticals

Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure.

Recommended Story: How Does the Quiet Period Work?

Insider Buying and Selling by Quarter for Dova Pharmaceuticals (NASDAQ:DOVA)

Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.